lan.png
EN
search.png
{$ImageUrl,alt}
Blog
home.png Home>Blog>Supercritical Nanotechnology & Liposomal Drug Delivery: Driving Litchlab’s Innovations in Nanomedicine

Supercritical Nanotechnology & Liposomal Drug Delivery: Driving Litchlab’s Innovations in Nanomedicine

Global pharmaceutical leader AstraZeneca has recently announced a licensing agreement with Nanoform, a Finland-based pharmaceutical technology company, to integrate supercritical fluid (SCF) nanotechnology for drug crystallization and optimization at the nanoscale. This cutting-edge technology demonstrates enormous potential in enhancing drug solubility and bioavailability, providing innovative solutions for poorly soluble drugs.

As a global leader in liposomal and nanomedicine drug delivery technologies, Litchlab is actively integrating SCF nanotechnology with its liposomal drug delivery platform to improve the stability and efficacy of RNA therapeutics, oncology drugs, and vaccines.

640 (6).png


Liposomal Nanomedicine: Precision Targeting for Enhanced Therapeutic Efficacy

Compared to traditional small-molecule drugs, liposomes have emerged as a core technology in nanomedicine due to their biocompatibility, high drug encapsulation efficiency, and controlled release properties. By combining supercritical nanotechnology, Litchlab is further optimizing liposomal drug delivery systems to advance RNA therapeutics, targeted cancer treatments, and vaccine development.

Key Advantages of Litchlab’s Liposomal Nanotechnology

Technical Feature

Litchlab’s Solution

Clinical Applications

Supercritical Liposome Preparation

Utilizes SCF technology for highly uniform and stable nanoparticles

mRNA delivery, poorly soluble APIs

Precision Particle Size Control (50–200 nm)

Enhances cellular uptake and improves biodistribution

siRNA, mRNA, and vaccine delivery

High Drug Encapsulation Efficiency

Optimized lipid compositions for improved stability of siRNA/mRNA therapeutics

Gene therapy, cancer immunotherapy

PEGylated Liposomes

Enhances circulation time and improves targeted delivery

Long-circulating RNA drugs, targeted cancer therapies

Targeted Functionalization

Antibody and aptamer modifications for tumor-specific delivery

Precision oncology, personalized medicine

 

Litchlab’s Liposomal Nanotechnology: Key Applications

1. RNA Therapeutics (mRNA / siRNA / ASO)

✅ mRNA Vaccine Delivery: Optimized LNPs for higher translation efficiency & enhanced immunogenicity
✅ siRNA Targeted Delivery: Increased stability and gene silencing efficiency
✅ ASO (Antisense Oligonucleotide) Delivery: Improved bioavailability, ideal for neurodegenerative diseases

2. Oncology Drug Delivery

✅ Liposomal Chemotherapy (e.g., Doxorubicin Liposomes): Reduced toxicity, improved efficacy
✅ siRNA + Small Molecule Co-Delivery: Gene regulation for enhanced treatment outcomes
✅ Immunotherapy Nanocarriers: Enhanced PD-1/PD-L1 checkpoint inhibitor efficiency

3. Vaccine Development

✅ mRNA Vaccines (e.g., COVID-19, Influenza): Stronger immune response, reduced degradation
✅ Protein Vaccine Liposomal Delivery: Enhanced antigen presentation & immune protection

4. Rare Diseases & Chronic Disease Management

✅ CRISPR/Cas9 Delivery for Gene Editing: Higher editing precision, reduced off-target effects
✅ Liposomal Sustained-Release Formulations: Long-acting drug delivery for improved patient compliance

How Litchlab Supports Pharmaceutical Innovation

Litchlab provides an end-to-end solution, from early-stage formulation development to GMP production, accelerating the transition of nanomedicine drug delivery platforms from lab to commercialization.

Technology Module

Litchlab’s Solution

Liposomal Drug Delivery Platform

Optimized formulations for enhanced RNA therapeutic efficiency

Scalable Production Technology

Microfluidics, high-pressure extrusion for GMP-grade manufacturing

Personalized Targeting

Antibody and aptamer-based targeting for precision medicine

Stability Optimization

Improved stability for RNA drugs, monoclonal antibodies (mAbs), and biologics

Nanoparticle Size Control

50–200 nm precise tuning for better tissue penetration


Future Outlook

The AstraZeneca-Nanoform collaboration marks a significant advancement in supercritical nanotechnology for poorly soluble drug delivery. Meanwhile, Litchlab is pioneering innovations in liposomal nanotechnology, revolutionizing RNA therapeutics, cancer treatments, and vaccine delivery. Moving forward, Litchlab will continue to partner with leading pharmaceutical companies to accelerate nanomedicine commercialization and bring next-generation therapeutics to patients worldwide.

For more information, please feel free to contact us at:  

E-Mail:RD2@Litchlab.com